BioSpace News Archive

SCYNEXIS, Inc. today announced one oral and two poster presentations of interim data from its Phase 3 FURI study, evaluating oral ibrexafungerp for the treatment of patients with refractory mucocutaneous and invasive fungal infections, will be presented at IDWeek 2021

Scopus BioPharma Inc. today announced it will be presenting at the Benzinga Healthcare Small Cap Conference on Wednesday, September 29, 2021.

Petros Pharmaceuticals, Inc. , announces today that President and Chief Commercial Officer Fady Boctor will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 - 30, 2021 .

Ayala Pharmaceuticals, Inc. today announced the publication of two case studies of adult patients with desmoid tumors treated with AL101 in Current Oncology .

Esker Therapeutics today announced that Martin Babler has joined the company as president, chief executive officer and chairman of the board of directors.

Horizon Therapeutics plc Announces Data Showing UPLIZNA ® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide shareholders and the market with an update to our market announcements of 8 June 2021 and 7 July 2021.

Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines

Actinium Pharmaceuticals, Inc. announced multiple senior leadership appointments including Arun Swaminathan, Ph.D., as Chief Business and Commercial Officer, Paul Diamond, Ph.D., as Vice President, Patent and Legal Counsel and Avinash Desai, M.D., who previously served as Executive Vice President, Clinical Development, Operations and Medical Affairs, to the position of Chief Medical Officer, effective immediately.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021.